{"success":true,"data":{"pressRelease":{"id":"155182","rtpr_id":"nNFC8ChwBl-20260929","ticker":"RHEL","exchange":"","all_tickers":["RHEL"],"title":"Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence","author":"Newsfile Corp","published_at":"2026-09-29T11:53:05.980Z","article_body":"* Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a\nPhase 2 trial of psilocybin-assisted therapy for post-traumatic stress\ndisorder in survivors of intimate partner violence.\nToronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life\nSciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) (\"Rhelion\" or the\n\"Company\") an Ontario-based organization advancing innovation and research\nwithin the legal psychedelic sector. Through its wholly owned subsidiary\nFilament Health Corp. (\"Filament\"), the Company develops, manufactures and\nsupplies PEX010, its patented, standardized, GMP manufactured botanical\npsilocybin drug candidate, to clinical research and compassionate access\nprograms at leading institutions worldwide.\n\nThe Company is pleased to announce that Filament has shipped PEX010 to the\nUniversity of Calgary for the Phase 2 trial titled \"Psilocybin-assisted\nTherapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner\nViolence\" (NCT06885996), known as PsiPTSD.\n\nPsiPTSD will evaluate psilocybin-assisted therapy for chronic post-traumatic\nstress disorder (PTSD) in adult survivors of intimate partner violence. The\ntrial is led by Dr. Chantel Debert at the University of Calgary. The\nUniversity of Calgary is the sponsor of the trial. Filament is not the sponsor\nof the trial and is not responsible for its conduct.\n\nPsiPTSD is the second trial led by Dr. Debert at the University of Calgary to\nuse PEX010, following a Phase 2b trial of psilocybin-assisted therapy for\npersisting symptoms after concussion (NCT06615908).\n\nPEX010, Filament Health's botanical psilocybin drug candidate, underscores\nFilament's position as a leading supplier of pharmaceutical grade natural\npsilocybin, supporting more than 80 academic and philanthropic research\nstudies worldwide. PEX010 is available in a standardized dosing range of 1, 5\nand 25 mg from a single drug candidate, with a 0.5 mg dose to follow, produced\nusing Filament's proprietary and patented extraction, purification and\nstabilization methods, giving investigators consistent composition across\nevery dose, every study and every research site. On April 30, 2026, the\nCompany completed its previously announced acquisition of Filament Health\nCorp., including its lead drug candidate, PEX010, and its portfolio of 78\nissued patents across 13 patent families.\n\nAbout Rhelion Life Sciences:\nRhelion Life Sciences is a science and research led company advancing the\nnatural psychedelic drug discovery and development sector. Through its wholly\nowned subsidiary Filament Health Corp., the Company is developing naturally\nderived psilocybin drug candidates, including its patented PEX010, and\nsupporting clinical research and compassionate use programs with leading\ninstitutions around the world.\n\nFor additional information:\nTodd Shapiro\nChief Executive Officer & Director\nTel: 647-204-7129\nEmail: todd@rhelion.com\nWebsite: www.Rhelion.com\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains certain \"forward-looking information\" within the\nmeaning of applicable Canadian securities legislation. Such forward-looking\ninformation and forward-looking statements are not representative of\nhistorical facts or information or current conditions but instead represent\nonly the Company's beliefs regarding future events, plans or objectives, many\nof which, by their nature, are inherently uncertain and outside of the\nCompany's control. Often, but not always, forward-looking statements and\ninformation can be identified by the use of words such as \"plans\", \"expects\"\nor \"does not expect\", \"is expected\", \"estimates\", \"intends\", \"anticipates\" or\n\"does not anticipate\", or \"believes\", or variations of such words and phrases\nor state that certain actions, events or results \"may\", \"could\", \"would\",\n\"might\" or \"will\" be taken, occur or be achieved. Examples of such information\ninclude statements with respect to: the supply of PEX010 to the PsiPTSD trial;\nthe conduct, enrolment and progress of the trial at its sites; the therapeutic\npotential of psilocybin-assisted therapy and PEX010, including for\npost-traumatic stress disorder in survivors of intimate partner violence;\ndemand for standardized natural psilocybin; the anticipated future\navailability of a 0.5 mg dose alongside the existing 1, 5 and 25 mg doses; the\ncompleted acquisition of Filament Health and the expected integration of\nFilament's clinical infrastructure and intellectual property; and the future\ndevelopment, commercialization and regulatory approval of PEX010.\n\nForward-looking information in this news release is based on certain\nassumptions and expected future events, namely: the continued ability of\nFilament and Psilo Scientific Ltd. to manufacture and supply PEX010; the\nperformance by the University of Calgary and Filament of their respective\nobligations under their agreement; the continued progression, enrolment and\nfunding of the trial; that the results of the trial will be consistent with\nprior research on psilocybin-assisted therapy for post-traumatic stress\ndisorder; the ability to obtain and maintain any required regulatory permits\nand approvals, including clinical trial, ethics, import and export\nauthorizations; the successful integration of Filament Health following the\ncompleted acquisition; and general business, market and economic conditions.\nRisks, uncertainties and other factors involved with forward-looking\ninformation could cause actual events, results, performance, prospects and\nopportunities to differ materially from those expressed or implied by such\nforward-looking information, namely: the risk that either party does not\nperform its obligations under their agreement; the risk that the trial does\nnot proceed, enrol or progress as anticipated; the risk that the trial does\nnot produce positive or clinically meaningful results; the risk that funding\nfor the trial is reduced, delayed or withdrawn; delays in regulatory\npermitting, including clinical trial, ethics, import and export\nauthorizations; regulatory or enforcement developments affecting the legal\nframework for psilocybin supply and research; the risk that the 0.5 mg dose\ndoes not become available as anticipated; the risk that integration of\nFilament Health is not completed as anticipated; and adverse changes in the\nregulatory or political landscape affecting psychedelic research and access,\ntogether with the other risk factors described in the Company's continuous\ndisclosure documents available under the Company's profile on SEDAR+ at\nwww.sedarplus.ca. Readers are cautioned that the foregoing list is not\nexhaustive.\n\nAlthough the Company believes that the assumptions and factors used in\npreparing, and the expectations contained in, the forward-looking information\nand statements are reasonable, undue reliance should not be placed on such\ninformation and statements, and no assurance or guarantee can be given that\nsuch forward-looking information and statements will prove to be accurate, as\nactual results and future events could differ materially from those\nanticipated in such information and statements. The forward-looking\ninformation and forward-looking statements contained in this press release are\nmade as of the date of this press release, and the Company does not undertake\nto update any forward-looking information and/or forward-looking statements\nthat are contained or referenced herein, except in accordance with applicable\nsecurities laws.\n\nSource: Rhelion Life Sciences Corp.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316514","article_body_html":"","raw_payload":{"data":{"id":"nNFC8ChwBl-20260929","title":"Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence","author":"Newsfile Corp","ticker":"RHEL","created":"2026-09-29T11:53:05.980Z","tickers":["RHEL"],"exchange":"","article_body":"* Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a\nPhase 2 trial of psilocybin-assisted therapy for post-traumatic stress\ndisorder in survivors of intimate partner violence.\nToronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life\nSciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) (\"Rhelion\" or the\n\"Company\") an Ontario-based organization advancing innovation and research\nwithin the legal psychedelic sector. Through its wholly owned subsidiary\nFilament Health Corp. (\"Filament\"), the Company develops, manufactures and\nsupplies PEX010, its patented, standardized, GMP manufactured botanical\npsilocybin drug candidate, to clinical research and compassionate access\nprograms at leading institutions worldwide.\n\nThe Company is pleased to announce that Filament has shipped PEX010 to the\nUniversity of Calgary for the Phase 2 trial titled \"Psilocybin-assisted\nTherapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner\nViolence\" (NCT06885996), known as PsiPTSD.\n\nPsiPTSD will evaluate psilocybin-assisted therapy for chronic post-traumatic\nstress disorder (PTSD) in adult survivors of intimate partner violence. The\ntrial is led by Dr. Chantel Debert at the University of Calgary. The\nUniversity of Calgary is the sponsor of the trial. Filament is not the sponsor\nof the trial and is not responsible for its conduct.\n\nPsiPTSD is the second trial led by Dr. Debert at the University of Calgary to\nuse PEX010, following a Phase 2b trial of psilocybin-assisted therapy for\npersisting symptoms after concussion (NCT06615908).\n\nPEX010, Filament Health's botanical psilocybin drug candidate, underscores\nFilament's position as a leading supplier of pharmaceutical grade natural\npsilocybin, supporting more than 80 academic and philanthropic research\nstudies worldwide. PEX010 is available in a standardized dosing range of 1, 5\nand 25 mg from a single drug candidate, with a 0.5 mg dose to follow, produced\nusing Filament's proprietary and patented extraction, purification and\nstabilization methods, giving investigators consistent composition across\nevery dose, every study and every research site. On April 30, 2026, the\nCompany completed its previously announced acquisition of Filament Health\nCorp., including its lead drug candidate, PEX010, and its portfolio of 78\nissued patents across 13 patent families.\n\nAbout Rhelion Life Sciences:\nRhelion Life Sciences is a science and research led company advancing the\nnatural psychedelic drug discovery and development sector. Through its wholly\nowned subsidiary Filament Health Corp., the Company is developing naturally\nderived psilocybin drug candidates, including its patented PEX010, and\nsupporting clinical research and compassionate use programs with leading\ninstitutions around the world.\n\nFor additional information:\nTodd Shapiro\nChief Executive Officer & Director\nTel: 647-204-7129\nEmail: todd@rhelion.com\nWebsite: www.Rhelion.com\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains certain \"forward-looking information\" within the\nmeaning of applicable Canadian securities legislation. Such forward-looking\ninformation and forward-looking statements are not representative of\nhistorical facts or information or current conditions but instead represent\nonly the Company's beliefs regarding future events, plans or objectives, many\nof which, by their nature, are inherently uncertain and outside of the\nCompany's control. Often, but not always, forward-looking statements and\ninformation can be identified by the use of words such as \"plans\", \"expects\"\nor \"does not expect\", \"is expected\", \"estimates\", \"intends\", \"anticipates\" or\n\"does not anticipate\", or \"believes\", or variations of such words and phrases\nor state that certain actions, events or results \"may\", \"could\", \"would\",\n\"might\" or \"will\" be taken, occur or be achieved. Examples of such information\ninclude statements with respect to: the supply of PEX010 to the PsiPTSD trial;\nthe conduct, enrolment and progress of the trial at its sites; the therapeutic\npotential of psilocybin-assisted therapy and PEX010, including for\npost-traumatic stress disorder in survivors of intimate partner violence;\ndemand for standardized natural psilocybin; the anticipated future\navailability of a 0.5 mg dose alongside the existing 1, 5 and 25 mg doses; the\ncompleted acquisition of Filament Health and the expected integration of\nFilament's clinical infrastructure and intellectual property; and the future\ndevelopment, commercialization and regulatory approval of PEX010.\n\nForward-looking information in this news release is based on certain\nassumptions and expected future events, namely: the continued ability of\nFilament and Psilo Scientific Ltd. to manufacture and supply PEX010; the\nperformance by the University of Calgary and Filament of their respective\nobligations under their agreement; the continued progression, enrolment and\nfunding of the trial; that the results of the trial will be consistent with\nprior research on psilocybin-assisted therapy for post-traumatic stress\ndisorder; the ability to obtain and maintain any required regulatory permits\nand approvals, including clinical trial, ethics, import and export\nauthorizations; the successful integration of Filament Health following the\ncompleted acquisition; and general business, market and economic conditions.\nRisks, uncertainties and other factors involved with forward-looking\ninformation could cause actual events, results, performance, prospects and\nopportunities to differ materially from those expressed or implied by such\nforward-looking information, namely: the risk that either party does not\nperform its obligations under their agreement; the risk that the trial does\nnot proceed, enrol or progress as anticipated; the risk that the trial does\nnot produce positive or clinically meaningful results; the risk that funding\nfor the trial is reduced, delayed or withdrawn; delays in regulatory\npermitting, including clinical trial, ethics, import and export\nauthorizations; regulatory or enforcement developments affecting the legal\nframework for psilocybin supply and research; the risk that the 0.5 mg dose\ndoes not become available as anticipated; the risk that integration of\nFilament Health is not completed as anticipated; and adverse changes in the\nregulatory or political landscape affecting psychedelic research and access,\ntogether with the other risk factors described in the Company's continuous\ndisclosure documents available under the Company's profile on SEDAR+ at\nwww.sedarplus.ca. Readers are cautioned that the foregoing list is not\nexhaustive.\n\nAlthough the Company believes that the assumptions and factors used in\npreparing, and the expectations contained in, the forward-looking information\nand statements are reasonable, undue reliance should not be placed on such\ninformation and statements, and no assurance or guarantee can be given that\nsuch forward-looking information and statements will prove to be accurate, as\nactual results and future events could differ materially from those\nanticipated in such information and statements. The forward-looking\ninformation and forward-looking statements contained in this press release are\nmade as of the date of this press release, and the Company does not undertake\nto update any forward-looking information and/or forward-looking statements\nthat are contained or referenced herein, except in accordance with applicable\nsecurities laws.\n\nSource: Rhelion Life Sciences Corp.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316514"},"type":"article","timestamp":"2026-09-29T11:53:06.048231543Z","server_sent_at_ms":1790682786048},"received_at":"2026-09-29T11:53:06.099Z","source_url":"https://www.newsfilecorp.com/release/316514"},"analysis":{"id":"143919","press_release_id":"155182","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Filament is a drug supplier only, not the trial sponsor — trial results are not directly attributable to the filer","Micro-cap psychedelic-sector name with regulatory and political risk to psilocybin research framework","Early-stage pipeline; no revenue-generating milestone attached to this announcement"],"eventType":"operations_update","narrative":"Filament Health, Rhelion's wholly owned subsidiary, has shipped PEX010 — its patented, GMP-manufactured botanical psilocybin — to the University of Calgary for PsiPTSD (NCT06885996), a Phase 2 trial of psilocybin-assisted therapy for PTSD in survivors of intimate partner violence.\n\nThe trial is led by Dr. Chantel Debert, who previously used PEX010 in a Phase 2b concussion-symptoms study; the University of Calgary is the sponsor and Filament is only the drug supplier.\n\nPEX010 now supports more than 80 research studies worldwide, and Rhelion completed its acquisition of Filament on April 30, 2026, adding 78 issued patents across 13 families — this shipment is incremental validation of that asset but not a company-sponsored trial.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Second University of Calgary trial using PEX010 reinforces Rhelion's supplier position in academic psychedelic research — modest positive, not a catalyst."},"keyFigures":{"drugName":"PEX010","phaseOfTrial":"Phase 2","customDimensions":{"trial_name":"PsiPTSD (NCT06885996)","issued_patents":78,"patent_families":13,"supporting_studies":80}},"quotedText":"Filament is not the sponsor of the trial and is not responsible for its conduct.","namedEntities":{"people":[{"name":"Dr. Chantel Debert","role":"trial lead, University of Calgary"},{"name":"Todd Shapiro","role":"CEO & Director"}],"products":["PEX010"],"companies":[{"name":"Rhelion Life Sciences Corp.","ticker":"RHEL","relationship":"filer/parent"},{"name":"Filament Health Corp.","relationship":"wholly owned subsidiary; PEX010 manufacturer/supplier"},{"name":"University of Calgary","relationship":"trial sponsor and research partner"},{"name":"Psilo Scientific Ltd.","relationship":"manufacturing counterparty referenced in assumptions"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"A supply shipment of the company's lead drug candidate PEX010 to a Phase 2 academic trial — a positive operational milestone for a micro-cap, but Filament is not the trial sponsor and no data, revenue, or capital event is involved."},"tickerRelevance":{"others":[{"ticker":"TRUFF","relevance":"OTCQB listing of the same issuer"},{"ticker":"4YX","relevance":"Frankfurt listing of the same issuer"}],"primary":"RHEL"},"globalImportance":12,"audienceRelevance":10,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"clinical-supply milestone, not company-sponsored data","issuerAuthored":true,"retailFavoriteBoost":false}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"Filament Health, Rhelion's wholly owned subsidiary, has shipped PEX010 — its patented, GMP-manufactured botanical psilocybin — to the University of Calgary for PsiPTSD (NCT06885996), a Phase 2 trial of psilocybin-assisted therapy for PTSD in survivors of intimate partner violence.\n\nThe trial is led by Dr. Chantel Debert, who previously used PEX010 in a Phase 2b concussion-symptoms study; the University of Calgary is the sponsor and Filament is only the drug supplier.\n\nPEX010 now supports more than 80 research studies worldwide, and Rhelion completed its acquisition of Filament on April 30, 2026, adding 78 issued patents across 13 families — this shipment is incremental validation of that asset but not a company-sponsored trial.","key_figures":{"drugName":"PEX010","phaseOfTrial":"Phase 2","customDimensions":{"trial_name":"PsiPTSD (NCT06885996)","issued_patents":78,"patent_families":13,"supporting_studies":80}},"named_entities":{"people":[{"name":"Dr. Chantel Debert","role":"trial lead, University of Calgary"},{"name":"Todd Shapiro","role":"CEO & Director"}],"products":["PEX010"],"companies":[{"name":"Rhelion Life Sciences Corp.","ticker":"RHEL","relationship":"filer/parent"},{"name":"Filament Health Corp.","relationship":"wholly owned subsidiary; PEX010 manufacturer/supplier"},{"name":"University of Calgary","relationship":"trial sponsor and research partner"},{"name":"Psilo Scientific Ltd.","relationship":"manufacturing counterparty referenced in assumptions"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:53:12.933Z","global_importance":12,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"clinical-supply milestone, not company-sponsored data","issuerAuthored":true,"retailFavoriteBoost":false}},"durationMs":6843,"modelName":"glm-5.3-flashx"}}